Drugs Xagena
The CDK 4/6 inhibitor Ribociclib ( Kisqali ) has been approved by the FDA ( Food and Drug Administration ) for use in combination with an aromatase inhibitor for the frontline treatment of postmenopau ...
The FDA ( US Food and Drug Administration ) has approved Kisqali ( Ribociclib ) for women with hormone-receptor positive, human epidermal growth factor receptor-2 negative ( HR+/HER2- ) advanced or me ...